PROM1 and glioblastoma: Thiazolyl Blue Tetrazolium Bromide (MTT) assay was performed to evaluate the functional effects of nanomedicine on the viability glioblastoma cells in the exposure of the developed nanodrug (Au-PEG-CD133-CB-839) and controls (Au-Cit, Au-PEG-COOH, native CB-839, Au-PEG-CD133) in the previously established concentration of 20 nM (Figure 8).